BridgeBio Pharma, Inc. 10-Q

Item 5. Other Information. None. 110 Item 6. E xhibits. Exhibit Number Exhibit Title Form File No. Exhibit Filing Date 3.1 Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect 8-K 001-38959 3.1 July 3, 2019 3.2 Amended and Restated Bylaws of the Registrant, as currently in effect 8-K 001-38959 3.2 July 3, 2019 4.1 Specimen Common Stock Certificate S-1 333- 231759 4.1 June 24, 2019 4.2 Registration Rights Agreement, dated June 26, 2019, among the Registrant and certain of its stockholders S-1 333-231759 4.3 May 24, 2019 4.3 Indenture, dated as of March 9, 2020, by and between BridgeBio Pharma, Inc. and U.S. Bank National Association, as Trustee 8-K 001-38959 4.1 March 10, 2020 4.4 Form of Global Note, representing BridgeBio Pharma, Inc.’s 2.50% Convertible Senior Notes due 2027 8-K 001-38959 4.2 March 10, 2020 10.1 Open Market Sale Agreement SM , dated as of July 7, 2020 S-3 333-239734 1.2 July 7, 2020 10.2 Agreement and Plan of Merger, dated as of October 5, 2020, by and among BridgeBio Pharma, Inc., Eidos Therapeutics, Inc., Globe Merger Sub I, Inc. and Globe Merger Sub II, Inc. 8-K 001-38959 2.1 O ctober 6, 2020 10.3# Amended and Restated 2019 Employee Stock Purchase Plan, effective December 12, 2019 — — — Filed herewith 31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith 31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith 32.1* Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith 32.2* Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 — — — Filed herewith 101.INS XBRL Instance Document — — — Filed herewith 101.SCH XBRL Taxonomy Extension Schema Document — — — Filed herewith 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document — — — Filed herewith 101.DEF XBRL Taxonomy Extension Definition Linkbase Document — — — Filed herewith 101.LAB XBRL Taxonomy Extension Label Linkbase Document — — — Filed herewith 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document — — — Filed herewith * This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing. # Indicates a management plan, contract or arrangement. 111 SIGNA TURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BridgeBio Pharma, Inc. Date: November 5, 2020 By: /s/ Neil Kumar Neil Kumar, Ph.D. Chief Executive Officer, Director (Principal Executive Officer) Date: November 5, 2020 By: /s/ Brian Stephenson Brian Stephenson, Ph.D., CFA Chief Financial Officer (Principal Financial Officer) 112